The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Ampersand Biomedicines Secures Series B Funding and Expands Partnership in Obesity
Mar 19, 2025•about 1 year ago
Contract Type
partnership
BostonBiotechnology
Description
Ampersand Biomedicines has secured $65 million in Series B funding from a group of investors including founder Flagship Pioneering and Eli Lilly & Company. The company has also initiated a second discovery partnership in obesity, and plans to advance two lead programs in immuno-inflammation and immuno-oncology.
Company Information
Company
Ampersand Biomedicines
Location
Boston, Massachusetts, United States
About
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.
BostonBiotechnology